The weird, the wacky and the wonderful has been on display in Las Vegas this week at CES – the world’s biggest consumer ...

Trump tariffs will loom over financial markets in 2025 but may not be as nasty as the president-elect previously flagged.

Aubiotech hopes to score some quick runs with a pre-budget submission on ways to fix the sector's "stubborn issues" ...

Other stars in December included Orthocell (ASX:OCC), which was up 67% amid “outstanding” clinical trial results and expected ...

Australian Mines (ASX:AUZ) is exploring potential production scenarios after nearly doubling its scandium resource in NSW.

The ASX keeps charging, while Wall Street slips on strong US data and Energy Transition Minerals pops on Trump's Greenland ...

Dual-listed regenerative medicine company Avita Medical has seen its share price slide ~19% today on a downgrade of its ...

After the benchmark S&P/ASX 200 surged 7.5 per cent in 2024, investors are looking to see where the growth will come from in ...

Cell therapies have suffered from hyped-up expectations, clinical setbacks and high costs. But maybe, just maybe, Arovella is ...

The advent of a Trump presidency is accelerating a divergence on digital currencies between the world’s two largest economies ...

ASX tech rocked a 50pc gain in 2024, Archer Materials shone in December, and Dubber and Brainchip cashed in on major ...

Kalamazoo Resources led materials sector gainers this morning as the release of drill assays from its Mallina West gold ...